BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1476 related articles for article (PubMed ID: 26235285)

  • 1. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison between CHOP-like and R-CHOP in diffuse large B cell and follicular lymphoma].
    Oliver C; Guillermo C; Martínez P; Díaz L
    Rev Med Chil; 2013 Jul; 141(7):844-52. PubMed ID: 24356732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era.
    Chen Y; Luo L; Chen L; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Yang T; Hu J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2311-2318. PubMed ID: 36219261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
    Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
    Pavlovsky M; Cubero D; Agreda-Vásquez GP; Enrico A; Mela-Osorio MJ; San Sebastián JA; Fogliatto L; Ovilla R; Avendano O; Machnicki G; Barreyro P; Trufelli D; Villanova P
    JCO Glob Oncol; 2022 Mar; 8():e2100265. PubMed ID: 35486884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
    Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
    [No Abstract]   [Full Text] [Related]  

  • 8. Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma.
    Tomita N; Takasaki H; Fujisawa S; Miyashita K; Ogusa E; Kishimoto K; Matsuura S; Sakai R; Koharazawa H; Yamamoto W; Fujimaki K; Fujita H; Ishii Y; Taguchi J; Kuwabara H; Motomura S; Ishigatsubo Y
    J Clin Exp Hematop; 2013; 53(2):121-5. PubMed ID: 23995108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R; Tomita N; Matsumoto C; Hattori Y; Matsuura S; Takasaki H; Hashimoto C; Fujita H; Fujisawa S; Ishigatsubo Y
    J Clin Exp Hematop; 2013; 53(2):107-14. PubMed ID: 23995106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.
    Wu JQ; Song YP; Su LP; Zhang MZ; Li W; Hu Y; Zhang XH; Gao YH; Niu ZX; Feng R; Wang W; Peng JW; Li XL; Ouyang XN; Wu CP; Zhang WJ; Zeng Y; Xiao Z; Liang YM; Zhuang YZ; Wang JS; Sun ZM; Bai H; Cui TJ; Feng JF
    Chin Med J (Engl); 2018 Aug; 131(15):1767-1775. PubMed ID: 30058572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
    Ren J; Asche CV; Shou Y; Galaznik A
    J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.
    Dürig J; Uhlig J; Gerhardt A; Ritter M; Hapke G; Heßling J; Staib P; Wolff F; Krumm K; von Weikersthal LF
    Cancer Med; 2023 Feb; 12(3):2739-2751. PubMed ID: 36017743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with
    Uryu H; Mishima Y; Tsuyama N; Yokoyama M; Nishimura N; Fukuta T; Shirouchi Y; Okabe T; Inoue N; Takeuchi K; Terui Y
    Leuk Lymphoma; 2021 Sep; 62(9):2141-2150. PubMed ID: 33749498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of patients with transformed lymphoma in the rituximab era.
    Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
    Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.
    Yuan J; Greiner TC; Fu K; Smith LM; Aoun P; Chan WC; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Weisenburger DD
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):488-497.e2. PubMed ID: 28842137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era.
    Lim RMH; Chan NPX; Khoo LP; Cheng CL; Tan L; Poon EYL; Somasundaram N; Farid M; Tang TPL; Tao M; Lim ST; Chan JY
    Sci Rep; 2020 Mar; 10(1):4373. PubMed ID: 32152442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of the transformation of follicular lymphoma to diffuse large B-cell lymphoma in the rituximab era: A population-based study.
    Zheng W; Liu M; Guan L; Wang S
    Cancer Med; 2024 Apr; 13(8):e7120. PubMed ID: 38629251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.
    Hong F; Habermann TM; Gordon LI; Hochster H; Gascoyne RD; Morrison VA; Fisher RI; Bartlett NL; Stiff PJ; Cheson BD; Crump M; Horning SJ; Kahl BS
    Ann Oncol; 2014 Mar; 25(3):669-674. PubMed ID: 24567515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Yuen S; Phillips TJ; Bannerji R; Marlton P; Gritti G; Seymour JF; Johnston A; Arthur C; Dodero A; Sharma S; Hirata J; Musick L; Flowers CR
    Am J Hematol; 2024 Jul; 99(7):1281-1289. PubMed ID: 38700035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.